Citations

Clear

2504 citation(s) found for "Wu, Benjamin".

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Wen, Patrick Y. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Groot, John de , Lim, Michael, Mellinghoff, Ingo K. , Perry, James, Weller, M, Blondin, Nicholas A., Butt, Omar H. , Damek, Denise M., Fuente, Macarena I. de la , Drappatz, Jan, Dunbar, Erin, Giglio, Pierre , Hyddmark, Emma Viktoria, Iwamoto, Fabio, Jaeckle, Kurt A. , Kim, Lyndon, Kling, Heather M., Lee, Eudocia Q., Mantica, Megan , Mikkelsen, Tom, Newton, Herbert B. , Walbert, Tobias , Weathers, Shiao‐Pei , Lassman, Andrew B. , Group, for the GBM AGILE Regorafenib Study, Alexander, Brian, Anker, Lars , Berry, Nicholas , Cloughesy, Tim, Connelly, Jennifer , Detry, Michelle A. , Fitzgerald, Mark, Gordon, Gary, Graves, Todd, Hu, Jethro , Hyddmark, Emma Maria Viktoria, Johnson, Adam, Kalabic, Marija, Lesser, Glenn J., Marion, Joe , Owen, Scott, Perry, James R, Peters, Katherine B., Powell, Ashley, Saunders, Christina T., Tanner, Kirk, Untch, Sarah, Wilcox, Emma, Yung, W. K. Alfred, Lim, Michael , Buxton, Meredith , de Groot, John , Mellinghoff, Ingo K , Weller, Michael , De La Fuente, Macarena , Lee, Eudocia Q , Mantica, Megan , Nabors, Louis Burt , Newton, Herbert B , Olson, Jeffrey J. , Schiff, David , Walbert, Tobias , Weathers, Shiao-Pei , Cloughesy, Timothy F , Lassman, Andrew B , Berry, Donald , Colman, Howard , Blondin, Nicolas, Drappatz, Jan , Iwamoto, Fabio M., Lee, Eudocia Q. , Mikkelsen, Tom , Nabors, Burt , Newton, Herbert B. , Cloughesy, Timothy F. , Anderson, Mark D., Cavenee, Webster K. , Connelly, Jennifer , Ellingson, Benjamin M. , Galanis, Evanthia , Gordon, Gary, Graber, Jerome J. , Khasraw, Mustafa , Lesser, Glenn J. , McGlothlin, Anna , Peters, Katherine B. , Saunders, Christina T. , Sulman, Erik P. , Tanner, Kirk, Yung, W.K. Alfred

Mayo Clinic

Journal of Clinical Oncology | April 14, 2026 | Volume: 44 | Issue: 18 | Pages: 1676-1686

10.1200/jco-25-01137 | PMID 41980234 Get It

PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Drilon, Alexander E., Cho, B , Camidge, D Ross, Nagasaka, Misako, Besse, Benjamin, Solomon, B, Goto, Koichi , Wolf, Jürgen, Popat, Sanjay , Felip, Enriqueta, Yang, Nong, Langen, A. de, Lu, Shun, Velcheti, Vamsidhar, Lin, Andrew , Calvet, C. , Tschaika, Marina, Afsar, Salman, Yang, Haisu, Lin, Jessica J., Solomon, Benjamin , Cho, Byoung Chul , Besse, Benjamin , Drilon, Alexander , Langen, Adrianus J. de , Drilon, Alexander , Nagasaka, Misako , Besse, Benjamin , de Langen, Adrianus Johannes , Lin, Andrew L , Popat, Sanjay , Solomon, Benjamin J , Camidge, David Ross , Wolf, Jürgen , Felip, Enriqueta , Yang, Nong, Velcheti, Vamsidhar , Afsar, Salman

Mayo Clinic

The Oncologist | April 14, 2026 | Volume: 31 | Issue: 6 | Pages: No page available

10.1093/oncolo/oyag137 | PMID 41992489 Get It

Abstract Background Repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor, is approved for ROS1 fusion-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. Its side effects and safety management strategies require further characterization. Patients and Methods The safety profile of repotrectinib (treatment-emergent/related adverse events [TEAEs/TRAEs]) was established in patients who initiated treatment at the recommended dose (160 mg daily [QD] for 14 days, then 160 mg twice daily [BID]) across all cohorts of the global, multicenter phase 1/2 TRIDENT-1 study. AE management strategies were outlined. Results In 472 patients, the most common TRAEs (dizziness [58%] and dysgeusia [50%]) were likely TRK inhibition-related. Median relative dose intensity was 90%; 14% (n = 66/472) of patients did not increase their initial QD dose to BID (mostly due to CNS AEs). Rates of dizziness (median onset, 7 days) were similar in patients with/without baseline brain metastases. Dose modifications downgraded severity or resolved dizziness in 78% of patients; 58% of patients had pharmacologic intervention without dose modification. Dizziness was downgraded/resolved in 62% (n = 120/195) of patients who did not receive dose modification or pharmacologic intervention. Treatment-related cognitive impairment and weight gain occurred in 19% and 12% of patients, respectively. Treatment-emergent withdrawal pain occurred in 14% of patients (median resolution time, 2.1 weeks). Dose interruption and reduction from TRAEs occurred in 39% and 38% of patients, respectively; 10% reported later re-escalation back to 160 mg BID. Conclusion Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.
Intratumoural oncolytic HSV-1 reshapes the local and systemic immune landscape through CD8 ⁺ T cell reprogramming
Appleton, Elizabeth Stefanie, Roulstone, Victoria , Portillo, Mikel, Hassan, Jehanne , Hubbard, Lisa, Kyula, Joan, Dean, Isaac , López, Ernesto , Pedersen, Malin , Rullan, Antonio, Tye, Chanidapa, Allen, Mark, Baldock, Holly , Rowley, Jessica, Patin, Emmanuel, Taylor, Alex, Wongariyapak, Amarin , Mohan, Nitya , Leslie, Isla, Liseth, Olivia , Vile, Richard, Arwert, Esther, Jones, Sylwia , Bommareddy, Praveen, Coffin, Robert, Harrington, K., Dean, Isaac , Appleton, Elizabeth , Patrikeev, Anton , Foo, Shane , Hubbard, Lisa, Kyula, Joan , Hak, Charleen Chan Wah , Tye, Chanidapa Adele , Patin, Emmanuel C. , Kendall, Benjamin L. , Vile, Richard G. , Arwert, Esther N. , Bommareddy, Praveen K. , Ono, Masahiro , Harrington, Kevin, Melcher, Alan

Mayo Clinic

No container title available | April 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.07.716986 Get It

Abstract Most oncolytic viruses are delivered by intratumoural injection, and local administration can induce regression of both injected and distant tumours in mice and patients. However, the mechanisms by which local viral infection reprograms systemic immunity remain poorly understood. Here we show that intratumoural RP1, an oncolytic HSV-1 encoding GM-CSF and GALV-GP-R ⁻ , drives regression of injected and uninjected murine melanoma tumours and prolongs survival. RP1 elicits coordinated CD4 ⁺ and CD8 ⁺ T cell infiltration accompanied by local cytokine remodelling, reshaping the immune landscape at both tumour sites. Leveraging the Timer of Cell Kinetics and Activity (Tocky) system and Kaede photoconvertible protein technology, we resolve the temporal dynamics of CD8 ⁺ T cell responses following local virotherapy and identify two systemically induced, virus-driven CD8 ⁺ T cell populations distinguished by TCR engagement kinetics: antigen-engaged Timer-positive ‘viral-induced precursors’ (VIPs) and Timer-negative KLRG1 ⁺ ‘viral-induced terminal effectors’ (VITEs). Single-cell transcriptomic and pseudotime analyses reveal divergent differentiation trajectories; VIPs exhibit sustained antigen engagement within the tumour microenvironment (TME), a transcriptional programme associated with self-renewal, and preferential homing to draining lymph nodes. A VIP-associated gene signature correlates with clinical response to RP1 plus PD-1 blockade in the IGNYTE trial of RP1 and nivolumab in PD-1-refractory melanoma and is independently associated with response to immune checkpoint inhibitor (ICI) therapy in melanoma. These findings establish a mechanistic link between local oncolytic virotherapy, systemic CD8 ⁺ T cell reprogramming, and durable regression of distant lesions in patients.
Acute Kidney Injury and Outcomes in the Cardiac Intensive Care Unit: Insights from the Critical Care Cardiology Trials Network
Padkins, Mitchell , Papolos, Alexander , Kenigsberg, Benjamin B. , Katz, Jason N., Diepen, Sean van, Steverson, Alexandra K., Rose, Scott W. , Wang, Jeffrey, Park, Jeong‐Gun , Barsness, Gregory W. , Jentzer, Jacob Colin, Diepen, Sean van , Singam, N Sarma V , Padkins, Mitchell R , van Diepen, Sean , Jentzer, Jacob C , Singam, Narayana Sarma V. , Berg, David D. , Katz, Jason N , Bohula, Erin A. , Morrow, David A. , Jentzer, Jacob C.

Mayo Clinic

Journal of Intensive Care Medicine | April 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261440201 | PMID 41954488 Get It

Background Acute kidney injury (AKI) is associated with high morbidity and mortality in critically ill patients. Multicenter analyses describing the epidemiology of AKI in the cardiac intensive care unit (CICU) are scarce. Here, we describe the prevalence, predictors, and outcomes associated with AKI in a contemporary multicenter CICU population. Methods The Critical Care Cardiology Trials Network (CCCTN) is a collaboration of CICUs in North America coordinated by the TIMI Study Group (Boston, MA). We evaluated patient and hospital-level outcomes as a function of creatinine-only Kidney Disease: Improving Global Outcomes (KDIGO) AKI stage within the CCCTN registry. Logistic regression was used to assess associations with in-hospital mortality. Results Among 21 603 admissions, the overall prevalence of AKI was 23.7%, which was composed of KDIGO stage 1: 12.7%, stage 2: 1.7%, and stage 3: 9.2%. A higher prevalence and severity of AKI were seen in patients with baseline kidney disease, hypertension, or diabetes and in admissions with heart failure, cardiogenic shock, and cardiac arrest ( P < .001 for all). There was a stepwise increase in hospital mortality across AKI stages (stage 1: 23%, stage 2: 39%, stage 3: 42%; P < .0001). The increased risk of death associated with progressive AKI stage persisted after multivariate adjustment (adjusted OR: stage 1: 2.1, stage 2: 3.7, stage 3: 3.4). Conclusions AKI occurs in 1 in 4 admissions to the CICU, and a higher AKI stage is incrementally associated with in-hospital mortality, highlighting a need to develop strategies to mitigate AKI and its complications.
NCCN Guidelines® Insights: Distress Management, Version 1.2026
Fann, Jesse R., Vanderlan, Jessica, Brewer, Benjamin W. , Corbett, Cheyenne , Keller, Jennifer A. , Lahijani, Sheila , Niazi, Shehzad K. , Riba, Michelle B., Braun, IIana, Breitbart, William S., Channa, Yamna, Farabelli, Jill P., Fleishman, Stewart B., Garcia, Sofia F. , Greenberg, Donna B., Handzo, George , Horyna, Amy, Hutchinson, Sean Z., Johns, Shelley A. , Cava, Shannon La, Martin, Sara , Mukherjee, Debraj, Pailler, Megan E. , Parnes, Francine, Rocha-Cadman, Xiomara, Scher, Eli D. , Schuster, Jessica, Thompson, Lora M.A., Usher, A., Valentine, Alan , Darlow, Susan, Mukherjee, Debraj , Mukherjee, Debraj , Garcia, Sofia F , Fann, Jesse R. , Andersen, Barbara L. , Atreya, Chloe Evelyn , Breitbart, William S., Greenberg, Donna, Huang, Chao‐Hui , Leeper, Heather , Rao, Vinay P. , Rocha‐Cadman, Xiomara , Thompson, Lora M.A., Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2026.0018 | PMID 41956112 Get It

These NCCN Guidelines for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer. They are intended to assist oncology teams to identify patients who require referral to psychosocial resources and to give oncology teams guidance on interventions for patients with significant distress. These guidelines also provide guidance for social workers, certified chaplains, and mental health professionals by describing treatments and interventions for various psychosocial problems as they relate to patients with cancer. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding standards of care for distress management in patients with cancer and implementation of these standards, including application of evidence-based care delivery models, such as the collaborative care model.
Extent and Progression of Cardiac Damage in Patients With Primary Mitral Regurgitation Undergoing Surgical Repair
Myagmardorj, Rinchyenkhand , Fortuni, Federico , Mantegazza, Valentina , Wijngaarden, A.K.S. van, Wu, Hoi Wai , Palmen, Meindert , Pepi, Mauro, Fusini, Laura , Muratori, Manuela , Essayagh, Benjamin , Tribouilloy, Christophe​, Tourneau, Thierry Le, Bohbot, Y, Michelena, Hector I, Bax, Jeroen J, Marsan, Nina Ajmone, Fortuni, Federico , Wijngaarden, Aniek L. van , van Wijngaarden, Aniek , Pepi, Mauro , Tribouilloy, Christophe , Le Tourneau, Thierry , Bohbot, Yohann , Michelena, Hector I , Enriquez-Sarano, Maurice , Bax, Jeroen J , Marsan, Nina Ajmone , Essayagh, Benjamin , Tribouilloy, Christophe , Tourneau, Thierry Le , Bohbot, Yohann , Michelena, Héctor I. , Enriquez‐Sarano, Maurice , Bax, Jeroen J. , Marsan, Nina Ajmone

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | April 9, 2026 | Volume: 68 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezag149 | PMID 41967857 Get It

Abstract Objectives The progression of extra-mitral valve (MV) cardiac damage in patients with primary mitral regurgitation (MR) following surgical repair has not been described. We aimed to investigate the evolution of extra-MV cardiac damage after MV repair and to assess its prognostic significance. Methods Patients with severe primary MR undergoing surgical repair at 5 referral centres were included when echocardiographic follow-up assessment was available. Based on echocardiographic parameters at baseline and at a median follow-up of 7 (interquartile range [IQR] 4-11) months after MV repair, patients were hierarchically classified as follows: stage 0: no cardiac damage; stage 1: left ventricular dilatation and/or dysfunction; stage 2: left atrial dilatation and/or atrial fibrillation; stage 3: pulmonary hypertension and/or significant tricuspid regurgitation. The primary outcome was all-cause mortality. Results A total of 764 patients (mean age 62 ± 13 years, 70% men) were included. Compared to baseline, 43% improved at least 1 stage, 49% remained unchanged, and 8% worsened at least 1 stage during follow-up after MV repair. At a median follow-up of 91 months after MV repair, 94 patients (12%) died. By multivariate Cox regression analysis, after adjusting for potential confounders, extra-MV cardiac damage staging at follow-up (HR per-1-stage-increase = 1.571; P = .009) and cardiac damage evolution (improved group, HR = 0.467; P = .034; worsened group, HR = 2.481, P = .037) were independently associated with all-cause mortality and had incremental prognostic value over preprocedural assessment. Conclusions Extra-MV cardiac damage improves significantly after MV repair, and its evolution is independently associated with all-cause mortality, suggesting the importance of comparative echocardiographic assessment following MV repair to improve risk stratification.
Primary Care Clinicians’ Attitudes on Digital Care Collaborative Management for Substance Use Disorders
Lai, Benjamin , Bormann, N. L., Arndt, Stephan, Smith, Jamie, Stoppel, Cynthia , Tuen, Kelsey, Cox, Danielle, Breitinger, Scott , Williams, Mark, Paul, Margaret, Lai, Benjamin , Bormann, Nicholas L. , Arndt, Stephan , Paul, Margaret M. , Oesterle, Tyler

Mayo Clinic

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | April 9, 2026 | Volume: 63 | Issue: No issue available | Pages: No page available

10.1177/00469580261440482 | PMID 41954165 Get It

Substance use disorders (SUD) remain a significant source of morbidity and mortality in the United States, and access to treatment continues to be inadequate. Primary Care Clinicians (PCCs) are well-positioned to provide long-term SUD care for patients. However, multiple provider-level barriers exist. Collaborative Care Management (CoCM) has proven successful in supporting PCCs in treating psychiatric conditions, such as depression. Our group proposes an addiction-focused modified CoCM that leverages telemedicine and an electronic platform (Senyo) into primary care. This study assesses PCCs’ attitudes toward this proposed model and their likelihood (with support) of prescribing medications for alcohol and opioid use disorder. To achieve this, an anonymized and confidential electronic survey was deployed to all 489 of our institutions’ PCCs. Eighty-five completed the survey (17.4% response); the majority (94%) agreed that digital CoCM for SUD will be helpful for their practice, and 85% expressed agreement that such a model will increase their confidence and likelihood to prescribe anti-craving medications. Additionally, we found that PCCs’ comfort level in addressing SUD with patients is not associated with years in practice, clinician type (attending physicians, resident/fellow physicians, nurse practitioner or physician assistant), or their perception of currently available SUD treatment resources. Future work to evaluate practice changes, including rates of anti-craving medication prescribing and SUD-treatment outcomes after implementation of our digital CoCM will prove useful in determining the effectiveness of this model.
Development and cross-site validation of machine-learning models for diagnosis and prognosis of stable angina with and without obstructive coronary artery disease: a study protocol
Deng, Jiawen, Patel, Shubh , Fung, Marinda, Heybati, Kiyan , Layard, Briana, Wang, Bo, Rubin, B., Hibbert, Benjamin, Anderson, Todd, Deng, Jiawen , Patel, Shubh K , Subasri, Vallijah , Deng, J , Simard, Trevor , Anderson, Todd J.

Mayo Clinic

BMJ Open | April 8, 2026 | Volume: 16 | Issue: 4 | Pages: e108799

10.1136/bmjopen-2025-108799 | PMID 41951258 Get It

Introduction Angina with no obstructive coronary artery disease (ANOCA) affects millions and is frequently under-recognised because diagnostic pathways and risk tools predominantly target obstructive coronary artery disease (CAD). This protocol describes shared methods for two machine-learning (ML) studies: (1) differentiating ANOCA from stable angina with obstructive CAD and (2) predicting long-term mortality among patients with ANOCA and obstructive CAD. Methods and analysis We will develop and cross-site validate ML classification models using a multicentre retrospective cohort drawn from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry and institutional datasets from the University of Ottawa Heart Institute and the University Health Network. Eligible participants are adults (≥18 years) undergoing initial cardiac catheterisation for chest pain/anginal equivalents since 1995, excluding prior revascularisation, major structural heart disease and predefined non-anginal indications. Outcomes are (1) ANOCA (0% to <50% stenosis) versus obstructive CAD (≥50% stenosis) and (2) 1, 3 and 5-year mortality, modelled separately for ANOCA and obstructive CAD. Model development will use nested cross-validation with stratified k-fold inner-loop tuning and leave-one-site-out cross-validation for repeated external validation. Candidate predictors will be harmonised across sites, filtered for missingness and refined using expert/directed acyclic graph-guided selection plus Boruta and Least Absolute Shrinkage and Selection Operator. Preprocessing includes appropriate encoding, missing-data imputation (multivariate imputation by chained equations) and feature scaling. Algorithms will include elastic-net logistic regression, random forest, LightGBM and multilayer perceptron models; hyperparameters will be optimised via Bayesian optimisation. Performance and threshold tuning will be reported. Explainability and subgroup fairness will be assessed using SHapley Additive exPlanations. Final models will be deployed as a web-based clinical risk calculator. Ethics and dissemination Ethics approval has been obtained from the University of Calgary and the University Health Network (#24-5916). Analyses will use deidentified data in secure environments; only aggregate results will be reported. Findings will be disseminated via peer-reviewed publications, conferences and a web-based calculator.
Multi-Contrast MRI Inputs Enable Self-Consistent Tissue Segmentation & Robust Perivascular Space Identification
Gunter, Jeffrey L. , Preboske, Gregory M., Persons, Benjamin D., Przybelski, Scott A. , Petersen, Ronald, Jack, Clifford R, Gunter, Jeffrey L , Persons, Benjamin, Schwarz, Christopher G. , Low, Audrey , Vemuri, Prashanthi , Jack, Clifford R.

Mayo Clinic

No container title available | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.03.716409 | PMID 41993560 Get It

Abstract Different MRI image contrasts are designed to highlight various tissue properties and combining them allows extension of probabilistic segmentation beyond the commonly used “gray-white-CSF” models. This work describes a fully automated method that combines T1-weighted, T2-FLAIR, and conventional T2-weighted images to provide internal consistency across prediction of tissue segmentations including segmentation of superficial and deep gray matter, white matter hyperintensities, and MR-visible perivascular spaces. Results from 773 imaging datasets from 403 participants in the Mayo Clinic Study of Aging and Mayo Clinic Alzheimer’s Disease Research Center (ADRC) are presented.
Comparison of neuropsychological side effects between contemporary radiofrequency ablative neurosurgery for psychiatric disorders and conventional neurosurgical procedures: systematic review and meta-analysis
Vilela-Filho, Osvaldo , Bannach, Matheus A., Lino-Filho, Adriano M. , Nuttin, Bart , Hariz, Marwan , Schulder, Michael , Greenberg, Benjamin David, Cosgrove, Rees, Oliveira-Souza, Ricardo de, Horn, Andreas, Sheth, Sameer A, Kubu, Cynthia S. , Salem, Sherif, Zaccariotti, Alice Jardim, Tavares, Naraiana O, Damasceno, Benito Pereira, Lozano, Andres M, Visser-Vandewalle, Veerle, Kühn, JP, Slavin, K. V., Lopes, A. Dwight, Vattimo, Edoardo FQ, Coyne, Terry, Akram, Harith, Toda, Hiroki , Halpern, Casey H. , Coenen, Volker A., Gorgulho, Alessandra, Andrade, Pablo, Wu, Hemmings , Sun, Bomin, Belmonte-De-Abreu, Paulo, Cosyns, Paul, McLaughlin, Nicole , Giordano, Prof. J., Berk, Michael, Chabardes, Stephan, Abbadi, Najia E, Salles, Antonio Afonso Ferreira De, Enslin, Nico, Sousa, Marcelo Basso de, Oliveira, José Oswaldo, Labruna, Rodrigo, Reis, Antonio Marcos dos , Jiménez-Ponce, Fiacro , Ferragut, Maria Alice, Régis, Jean, Lipsman, Nir , Rezai, Ali R. , Schuurman, Rick, Martínez-Álvarez, Roberto, Broggi, Giovanni, Huys, Daniel, Bervoets, Chris , Oliveira, P. A., Ragazzo, Paulo C., Lazaro-Munoz, Gabriel, Polosan, Mircea , Naesström, Matilda, Ribeiro, Telma MC, Lee, Kendall H, Hodaie, Mojgan , Sitnikov, Andrey, Yilmaz, Atilla, Almahariq, F., Rios, Adriana L Lopez, Gonçalves-Ferreira, António, Lozano, Andrés M. , Huys, Daniel , Enslin, Nico , Nuttin, Bart , Hariz, Marwan , Sheth, Sameer A , Damasceno, Benito Pereira , Kuhn, Jens , Slavin, Konstantin V. , Doshi, Paresh , Toda, Hiroki , Andrade, Pablo , Zrinzo, Ludvic , Chabardes, Stephan , Chang, Jin Woo , Polosan, Mircea , Hodaie, Mojgan , Almahariq, Fadi , Nico Enslin, Johannes M , Hamani, Clement , Greenberg, Benjamin D. , Oliveira‐Souza, Ricardo de , Sheth, Sameer A. , Zaccariotti, Alice Jardim , Tavares, Naraiana de Oliveira , Mayberg, Helen S. , Visser-Vandewalle, Veerle E. R. M. , Falkai, Peter , Lopes, Antonio C, Vattimo, Edoardo Filippo de Queiroz , Akram, Harith , Blomstedt, Patric C. , Quevedo, João , Belmonte-de-Abreu, Paulo Silva , Alkhani, Ahmed M. , Berk, Michael , Yatham, Lakshmi N. , Abbadi, Najia El , Salles, Antonio A. F. De, Chang, Jin Woo , Régis, Jean , Torres, Cristina V. , Taira, Takaomi , Barcia, Juan Antonio , Schuurman, Rick , Dougherty, Darin Dean , Giacobbe, Peter , Lázaro‐Muñoz, Gabriel , Naesström, Matilda , Johansson, Viktoria , Schlaepfer, Thomas Eduard , Neimat, Joseph S. , Sitnikov, A., Yilmaz, Atilla, Almahariq, Fadi, Ríos, Adriana Lucia López , Gonçalves-Ferreira, António JC.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | April 7, 2026 | Volume: 97 | Issue: 6 | Pages: 532-541

10.1136/jnnp-2025-337800 | PMID 41946555 Get It

Background Psychiatric disorders are increasingly contributing to global disability. Despite advances in conservative management, the prevalence of treatment-resistant cases remains high. Meanwhile, neurosurgery for psychiatric disorders (NPD) remains underused, largely due to strict regulations and historical concerns, particularly those related to neuropsychological side effects (NPSE). Objective To address this issue, we conducted a systematic review with meta-analysis to compare NPSE associated with radiofrequency ablative NPD to those observed in neuro-oncological, neurovascular and epilepsy surgeries. Methods PubMed, Embase and LILACS databases were searched in April 2024 for articles published in English/Spanish from 1990 to 2022, following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results A total of 48 articles with 2678 participants were included. The frequency of transient and permanent NPSE in the NPD group ranged from 0.94% to 11.50% and 0.94% to 2.03%, respectively, comparable to the other surgical groups (epilepsy: 0.31–11.70%; vascular: 0.52–22.90%; oncology: 0.94–17.60% for transient NPSE; epilepsy: 0.31–12%; vascular: 0.40–1.96% and oncology: 0.84–1.48% for permanent NPSE). Regarding permanent NPSE, arguably the most critical consideration, the NPD group showed better outcomes in memory, language and social cognition than the epilepsy group, but worse outcomes in executive and perceptual-motor functions. Compared with the vascular group, the NPD group had better executive function but worse complex attention. Finally, the NPD group had fewer permanent deficits than the oncology group in executive function, complex attention and perceptual-motor domains, although language performance was lower. Conclusions Contemporary NPD apparently carries a similar risk of NPSE as other conventional neurosurgical procedures, challenging misconceptions and this unjustified barrier to its broader use.